- A. Health Biotechnology
- Areas of activity
- In vitro diagnostics
- Therapeutic areas
- Infectious diseases
- Gynaecology and obstetrics
- Respiratory and pulmonary system
- D. Services
- R&D services
- Biotechnolgy kits
- CRO / CMO / SMO
- Professional services
Reig Jofre is a multinational pharmaceutical company based in Barcelona, market leader in the field of complex generic drugs, with the capacity to successfully develop, produce and commercialize injectables / lyophilizates and antibiotics derived from penicillins and cephalosporins.
Reig Jofre is committed to R&D as one of the pillars of its growth strategy, with a commitment to offer a wide range of value-added products, from prescription products that address unmet needs, to over-the-counter products and nutritional supplements intended for the maintenance of health. The R & D team associated with the injectable unit and its center of excellence dedicated to the study of lyophilization processes, has a long history in the stabilization of complex molecules, proteins, peptides and biological, as well as in analytical development Associated to lyophilization processes and quality control.
Reig Jofre has more than 900 employees, 4 development centers and 4 production centers in Europe, direct sales in 6 countries in Europe and more than 130 business partners in 63 countries worldwide. The company closed 2016 with a turnover of 161 million euros.
Reig Jofre is listed on the Spanish stock market under the RJF code.
Reig Jofre is active in two main areas: a principal dedicated to the development, production and commercialization of its own specialty products in antibiotics and injectables; of therapeutic specialty in the areas of dermatology, gynecology and respiratory; and nutritional supplements and consumer healthcare. And a complementary area in development and specialized production for third parties.